Evidence map›Paper›PMID 37460862›Full record

ArticleBiochemical genetics2024

DTX3L Accelerates Pancreatic cancer Progression via FAK/PI3K/AKT Axis.

Liang Chen, Wenyang Niu, Hong Zang, Yudong Qiu

Abstract read
PubMed Publisher
In one paragraph

Article in Biochemical genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Liang Chen *Department of Hepatobiliary Pancreatic Center, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, No. 321 Zhongshan Road, Nanjing, 210008, Jiangsu Province, China.
Wenyang Niu *Department of Hepatobiliary Surgery, Nantong First People's Hospital, the Second Affiliated Hospital of Nantong University, #6 Hai'Er Xiang North Road, Nantong, 226001, Jiangsu Province, China.
Hong ZangDepartment of Hepatobiliary Surgery, Nantong First People's Hospital, the Second Affiliated Hospital of Nantong University, #6 Hai'Er Xiang North Road, Nantong, 226001, Jiangsu Province, China. ntzanghong@sina.com.
Yudong QiuDepartment of Hepatobiliary Pancreatic Center, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, No. 321 Zhongshan Road, Nanjing, 210008, Jiangsu Province, China. qiuyudong289@163.com.
Affiliated Hospital of Nantong University · CNNanjing Medical University · CNNantong University · CN

Funding

National Key Research and Development Program of China 2020YFA0713804National Natural Science Foundation of China 31971518
6 · The paper itself

Abstract

DTX3L (Deltex E3 ubiquitin ligase 3 L) is an E3 ubiquitin ligase, a member of the deltex family. It is also known as B-lymphoma and BAL-associated protein (BBAP). DTX3L has been proven to play an important role in various tumor development; however, its role in pancreatic cancer remains unknown. So, we analyzed the DTX3L expression in pancreatic cancer based on the TCGA database and verified it in our samples by qRT‑PCR and western blot. We identified that DTX3L was highly expressed in pancreatic cancer, and its expression level was significantly negatively correlated with patients' survival. Using CCK8, colony formation, transwell, and wound healing assays, we found that upregulated DTX3L promotes pancreatic cancer cell proliferation, invasion, and migration. Mechanically, DTX3L combined with EGFR (epidermal growth factor receptor) and prevented the ubiquitination degradation of it. Upregulated EGFR activated the FAK/PI3K/Akt pathway and promoted the progression of pancreatic cancer. Moreover, we found that DTX3L can weaken pancreatic cancer cells' sensitivity to chemotherapy using the orthotopic implant tumor model. In conclusion, DTX3L accelerates pancreatic cancer progression by EGFR dependent FAK/PI3K/Akt pathway activation and may become a potential target for pancreatic cancer treatment.

Indexed as

Pancreatic NeoplasmsProto-Oncogene Proteins c-aktCell Line, TumorCell MovementCell ProliferationErbB ReceptorsHumansPhosphatidylinositol 3-KinasesUbiquitin-Protein LigasesDTX3L protein, humanErbB ReceptorsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktUbiquitin-Protein LigasesDTX3LFAK/PI3K/Akt axisPancreatic cancer

Identifiers

PMID37460862
OpenAlexW4384521882

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.